POY_1170x120_8-12-19

Medicaid Drug Rebate Program

Mylan, DOJ finalize settlement on EpiPen

Mylan, DOJ finalize settlement on EpiPen

PITTSBURGH — Mylan Inc. and Mylan Specialty L.P. have entered an agreement with the U.S. Department of Justice finalizing the $465 million Medicaid drug rebate settlement last fall. Mylan said late Thursday that the settlement, announced Oct. 7, resolves claims over the classification of the EpiPen and EpiPen Jr epinephrine auto-injectors in the Medicaid Drug

Implications of final AMP rule for community Rx

Implications of final AMP rule for community Rx

On February 1, 2016, the Centers for Medicare & Medicaid Services (CMS) released its Final Rule interpreting the provisions of the 2010 health care reform law that address the Medicaid Drug Rebate Program (MDRP). While much of the Final Rule speaks to drug manufacturer rights and responsibilities in the MDRP, significant portions are directly applicable

Final AMP-based FULs coming soon

Final AMP-based FULs coming soon

The National Association of Chain Drug Stores reports that final average manufacturer price (AMP)-based federal upper limits (FULs) are set to be published by the Centers for Medicare & Medicaid Services (CMS) late this month. Once instituted, the final AMP-based FULs will “significantly change” Medicaid pharmacy reimbursement for branded and generic drugs, according to NACDS.

Industry eyes CMS final rule for Rx reimbursement

Industry eyes CMS final rule for Rx reimbursement

WASHINGTON — The Centers for Medicare & Medicaid Services (CMS) has issued the Covered Outpatient Drugs final rule with comment, which the National Association of Chain Drug Stores said includes “significant changes” to Medicaid pharmacy reimbursement for generic drugs based on the average manufacturer price (AMP) model. Released on Thursday and due to be published